BME100 f2016:Group14 W1030AM L1

From OpenWetWare

Jump to: navigation, search
BME 100 Fall 2016 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help
Image:BME494_Asu_logo.png


Contents

Group 14

Name:Kyle Aubel
Name:Kyle Aubel
Name: Tina Kaing
Name: Tina Kaing
Name: Jose Galaviz
Name: Jose Galaviz
Name: Kevin Shultz
Name: Kevin Shultz
Name: Norberto Rodriguez Marquez
Name: Norberto Rodriguez Marquez
Name: Your name
Name: Your name

LAB 1 WRITE-UP

Health Care Issue

Diabetes, a group of metabolic diseases, begins when the pancreas is unable to produce sufficient insulin, or when it is incapable of responding to insulin produced in a proper way. This causes levels of sugar to rise over extended periods of time. There exist several types of diabetes, but Type 1 and 2 diabetes are the most common forms. Both forms impact glucose levels, and if it is not treated in the proper way, they can cause many complications, such as: extreme thirst, frequent urination, drowsiness, sudden vision changes, heavy breathing, and unconsciousness among others. Diabetes management is a chronic health condition but it can be managed with proper care from doctors. Monitoring blood sugar levels several times per day is a must for those who are diagnosed with diabetes type 1 or 2. To control sugar levels, patients with type 1 must inject insulin several times a day and self-monitor blood sugar levels. To simplify this process of getting the right dose of insulin in the moment that is needed, we came up with a new device. A small diabetes implant that automatically regulates insulin by self-releasing bar.
<http://donate.jdrf.org/info/jdrf-qa/#about> http://www.webmd.com/diabetes/guide/how-test-blood-glucose





Competitors

Implant
Daily injections
Daily pills
Self-releasing bar vs. Lancet (pricking needle)
Advantages
Not having to prick fingers multiple times a day in order to determine blood sugar convenience.
Life span.
Ease of mind.
Don’t need to buy as frequently.
Automatically release amount of insulin when needed.
Not painful.
Don’t have to carry around.

Disadvantages
Yearly/monthly injection
Malfunctions
Cost
Possibly aesthetically displeasing
Can’t buy at pharmacies.
A qualified physician would have to implant the device.
Might cause little discomfort at first.
Might be visible.




Link title

Customer Validation

Patient
Anyone with Type 1 or Type 2 Diabetes- Provides greater convenience by removing the need to prick one's finger to test blood sugar levels throughout the day.


Payer
Health Insurance- Covering the expenses of inserting the device
Lowers the need for expenses on Lancing devices, blood glucose test strips, insulin injections, insulin pills.

Physician
Doctors- Allows doctors to provide patients with a longer lasting and more convenient alternative to maintaining a desired blood glucose level.


Provider
Hospitals
Pharmaceuticals- allows for the sale of the device (profit)
Physicians- allows for the service of inserting the device (profit)

Purchaser
Novo Nordisk, a global healthcare company with more than 90 years of innovation and leadership in diabetes care.
< http://www.novonordisk-us.com/ >

MannKind Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients. In 2014, they had approved a rapid-acin inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. < http://www.mannkindcorp.com/ >

physicians- allows for more variety of treatments to offer to patients

IP Position

Strong issued patents, the birth control bar is already manufactured,used, and FDA approved

"Treatment of Side Effects of Progestins and Progesterone Analogues Used for Birth Control." US5744463A. N.p., n.d. Web. 31 Aug. 2016.


Fundability Worksheet Scores

Competitors
2 or 3

Customer Validation
2 or 3

IP Position
2 or 3


Personal tools